[1]Khan KS, Wojdyla D, Say L, et al. WHO analysis of causes of maternal death: a systematic review [J]. Lancet, 2006, 367(9516): 1066-1074.
[2]Wilkerson RG, Ogunbodede A. Hypertensive disorders of pregnancy [J]. Emerg Med Clin N Am, 2019, 37(2): 301-316.
[3]Umesawa M, Kobashi G. Epidemiology of hypertensive disorders in pregnancy: prevalence, risk factors, predictors and prognosis [J]. Hypertens Res, 2017, 40(3): 213-220.
[4]Ye C, Ruan Y, Zou L, et al. The 2011 survey on hypertensive disorders of pregnancy (HDP) in China: prevalence, risk factors, complications, pregnancy and perinatal outcomes [J]. PLoS One, 2014, 9(6): e100180.
[5]Shah DA, Khalil RA. Bioactive factors in uteroplacental and systemic circulation link placental ischemia to generalized vascular dysfunction in hypertensive pregnancy and preeclampsia [J]. Biochem Pharmacol, 2015, 95(4): 211-226.
[6]Liu J, Chen X, Hao S, et al. Human chorionic gonadotropin and IL-35 contribute to the maintenance of peripheral immune tolerance during pregnancy through mediating the generation of IL-10+ or IL-35+ Breg cells [J]. Exp Cell Res, 2019, 383(2): 111513.
[7]Nath MC, Cubro H, Mccormick DJ, et al. Preeclamptic women have decreased circulating IL-10 (Interleukin-10) values at the time of preeclampsia diagnosis: systematic review and metaanalysis [J]. Hypertension, 2020, 76(6): 1817-1827.
[8]A SY. Effects of IL-10, PXR and CYP3A4 gene polymorphisms on the pharmacokinetics of fasting and postprandial oral amlodipine in healthy Chinese subjects [D]. Nanchang:Nanchang University, 2017. (in Chinese)
阿萨亚. IL-10, PXR 和 CYP3A4 基因多态性对中国健康受试者空腹及餐后口服氨氯地平药代动力学特征的影响 [D]. 南昌:南昌大学, 2017.
[9]S?rensen LK, Havemose-Poulsen A, Bendtzen K, et al. Aggressive periodontitis and chronic arthritis: blood mononuclear cell gene expression and plasma protein levels of cytokines and cytokine inhibitors [J]. J Periodontol, 2009, 80(2): 282-289.
[10]Garovic VD, White WM, Vaughan L, et al. Incidence and long-term outcomes of hypertensive disorders of pregnancy [J]. J Am Coll Cardiol, 2020, 75(18): 2323-2334.
[11]Michalczyk M, Celewicz A, Celewicz M, et al. The role of inflammation in the pathogenesis of preeclampsia [J]. Mediators Inflamm, 2020, 2020: 3864941.
[12]Peixoto AB, Araujo Junior E, Ribeiro JU, et al. Evaluation of inflammatory mediators in the deciduas of pregnant women with pre-eclampsia/eclampsia [J]. J Matern Fetal Neonatal Med, 2016, 29(1): 75-79.
[13]Chatterjee P, Chiasson VL, Kopriva SE, et al. Interleukin 10 deficiency exacerbates toll-like receptor 3-induced preeclampsia-like symptoms in mice [J]. Hypertension, 2011, 58(3): 489-496.
[14]Valencia-Ortega J, Zárate A, Saucedo R, et al. Placental proinflammatory state and maternal endothelial dysfunction in preeclampsia [J]. Gynecol Obstet Invest, 2019, 84(1): 12-19.
[15]Gharesi-Fard B, Mobasher-Nejad F, Nasri F. The expression of T-helper associated transcription factors and cytokine genes in pre-eclampsia [J]. Iran J Immunol, 2016, 13(4): 296-308.
[16]Bordaeva O, Umanskiy M, Derevyanchuk E, et al. Association of IL-10 and F2 and F5 blood clotting factors genes polymorphisms with Pre-eclampsia risk [J]. Online J Health Allied Scs, 2019, 18(2): 1-5.
[17]Sowmya S, Sri Manjari K, Ramaiah A, et al. Interleukin 10 gene promoter polymorphisms in women with early-onset pre-eclampsia [J]. Clin Exp Immunol, 2014, 178(2): 334-341.
[18]Fan D, Wang Y, Liu X, et al. Polymorphisms in interleukin-6 and interleukin-10 may be associated with risk of preeclampsia [J]. Genet Mol Res, 2017, 16(1): 16018588.
[19]Afkari B, Babaloo Z, Dolati S, et al. Molecular analysis of interleukin-10 gene polymorphisms in patients with Beh et’s disease [J]. Immunol Lett, 2018, 194(12): 56-61.
|